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Connective tissue growth factor (CTGF) is secreted by ﬁbroblasts stimulated with transforming growth factor-b
(TGF-b). CTGF is a potent enhancer of ﬁbroblast proliferation, chemotaxis, and extracellular matrix deposition, and
it is thought to mediate some of the ﬁbrogenic effects of TGF-b. Here, we have elucidated signaling pathways
involved in regulating the TGF-b-induced production of CTGF in primary ﬁbroblasts. TGF-b induced the expression
of CTGF messenger RNA and protein in human gingival ﬁbroblasts after 2 h of treatment. Adenoviral overexpres-
sion of Smad3 enhanced the TGF-b-elicited expression of CTGF, whereas Smad7 and dominant-negative Smad3
suppressed the effects of TGF-b on CTGF and Cyr61 expression. Pre-treatment of cells with PD98059, an inhibitor
for extracellular signal-regulated kinase (ERK)1/2-activator mitogen-activated protein kinase (MAPK)/ERK kinase
(MEK)1, potently inhibited the TGF-b-induced expression of CTGF. Furthermore, co-expression of Smad3 with
constitutively active MEK1 resulted in potent induction of CTGF production without exogenous TGF-b stimulation.
Together, these results demonstrate that Smad3 and ERK1/2 coordinately mediate TGF-b-induced release of CTGF
by ﬁbroblasts. It is conceivable that the crosstalk between Smad3 and ERK1/2 signaling cascades plays an im-
portant role in regulating CTGF expression, e.g., in wound repair and tissue ﬁbrosis and could be exploited in
therapeutic targeting of ﬁbrotic conditions.
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Connective tissue growth factor (CTGF) is a 36–38 kD
cysteine-rich heparin-binding protein originally discovered
in the conditioned medium of human umbilical vein end-
othelial cells. CTGF belongs to the CCN (CTGF, Cyr61, and
nephroblastoma overexpressed (Nov)) family of growth fac-
tors, the additional members of which include Elm-1/Wnt1-
inducible signaling pathway protein (WISP-1), Cop1/WISP-
2, and WISP-3. CTGF exhibits diverse cellular functions
depending on the cell type, which include matrix produc-
tion, cell migration, angiogenesis, and cell adhesion. Trans-
forming growth factor-b (TGF-b) induces the expression of
CTGF in connective tissue cells, but not in epithelial cells
(Grotendorst, 1997; Holmes et al, 2001; Chen et al, 2002;
Leask et al, 2003). Thus, CTGF is thought to mediate
the stimulatory effects of TGF-b on proliferation and matrix
production by fibroblastic cells. In addition, CTGF stimu-
lates the synthesis of type I collagen and fibronectin (Frazier
et al, 1996), and appears to account for the profibrogenic
effects attributed to TGF-b.
The cellular effects of TGF-b are mediated via Smad and
mitogen-activated protein kinase (MAPK) signaling pathways
(Massague, 2000). TGF-b-activated Smad transription fac-
tors are divided into three groups according to their function:
receptor-activated Smad (Smad2 and Smad3), common-
mediator Smad (Smad4), and inhibitory Smad (Smad7). Re-
ceptor-activated Smad2 and Smad3 are phosphorylated by
activated TGF-b receptor complex, and following phosphor-
ylation these Smads associate with Smad4. Subsequently,
this hetero-oligomeric complex translocates into the nucle-
us, where Smads bind to DNA or associate with other tran-
scription co-activators or co-repressors, and regulate the
transcription of various TGF-b-responsive genes (Massague
and Wotton, 2000). Smad7 is an inhibitory Smad, the ex-
pression of which is induced by TGF-b, and that is capable
of inhibiting phosphorylation of Smad2 and Smad3 by com-
petitively interacting with the TGF-b receptor complex
(Nakao et al, 1997).
In addition to Smad, TGF-b signaling is mediated via
MAPK pathways. TGF-b can activate distinct MAPKs in-
Abbreviations: CCN, Cyr61, CTGF, Nov family; CTGF, connective
tissue growth factor; Cyr61, cysteine-rich 61; ECM, extracellular
matrix; ERK, extracellular signal-regulated kinase; JNK, c-Jun
N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK,
MAPK/ERK kinase; MKK, MAPK kinase; MMP, matrix metal-
loproteinase; MOI, multiplicity of infection; Nov, nephroblastoma
overexpressed; PAI, plasminogen activator inhibitor; TGF-b,
transforming growth factor-b; TIMP, tissue inhibitor of metal-
loproteinases; WISP, Wnt-induced secreted protein
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cluding extracellular signal-regulated kinase (ERK)1/2, c-
Jun N-terminal kinase (JNK), and p38 in various types of
cells. In human gingival fibroblasts, TGF-b stimulation re-
sults in the activation of ERK1/2 and p38 MAPK pathways
(Ravanti et al, 1999). There is evidence for crosstalk be-
tween distinct cell signaling cascades activated by TGF-b,
e.g., MAPK and Smad pathways. ERK1/2, JNK, and p38
MAPK are capable of activating or inhibiting Smad pathway
by phosphorylating Smad2 or Smad3 ( de Caestecker et al,
1998; Brown et al, 1999; Dennler et al, 2000; Leivonen et al,
2002; Hayashida et al, 2003). In addition, delayed phos-
phorylation of p38 MAPK by TGF-b has recently been
shown to be mediated by the Smad pathway (Takekawa
et al, 2002; Ungefroren et al, 2003).
The promoter region of CTGF contains a TGF-b response
element, which is mainly responsible for the basal expres-
sion of CTGF (Grotendorst, 1997; Holmes et al, 2001). In
addition, a functional Smad binding element has been iden-
tified from the CTGF promoter, and it is essential for TGF-b
induction of CTGF promoter activity in lung and skin fibro-
blasts, and in mesangial cells (Holmes et al, 2001; Chen
et al, 2002). There is also recent evidence that activation of
Ras/MAPK/ERK kinase (MEK)1/2/ERK1/2 pathway is re-
quired for activation of CTGF promoter by TGF-b in fibro-
blasts (Leask et al, 2003). Here, we have elucidated the role
of Smad and MAPK signaling in the regulation of endog-
enous CTGF in human gingival fibroblasts. Our results
show, that TGF-b potently induces secretion of soluble
CTGF in fibroblasts, and that this is mediated by cooper-
ation between ERK1/2 and Smad3 signaling pathways. It is
conceivable that this interplay may play an important role in
regulating CTGF expression, e.g., in wound repair and tis-
sue fibrosis and could be exploited in therapeutic targeting
of CTGF expression in fibrotic conditions.
Results
TGF-b induces the expression of CTGF in human gin-
gival ﬁbroblasts TGF-b induces the expression of CTGF in
human dermal fibroblasts (Igarashi et al, 1993). To also ex-
amine whether human gingival fibroblasts express CTGF in
response to TGF-b, we treated human gingival fibroblasts
obtained from three different donors with TGF-b (5 ng per
mL) for 24 h, and analyzed the expression of CTGF by
northern and western blots. CTGF is a secreted protein that
can exist as a soluble 36–38 kDa glycosylated form, or al-
ternatively, it can be associated with the cell layer (Steffen
et al, 1998). As shown in Fig 1A, a 24-h TGF-b stimulation
led to potent induction of CTGF production both in to the
conditioned media and the cell layers of all gingival fibro-
blast strains studied. Cyr61 protein was detected in the cell
layers of gingival fibroblasts, and its expression was also
potently upregulated by TGF-b. In comparison, the levels of
tissue inhibitor of metalloproteinases-1 (TIMP-1) in the con-
ditioned media of fibroblasts remained unaltered in re-
sponse to TGF-b (Fig 1A).
We also studied the kinetics of TGF-b induction of CTGF
expression by treating the cultures with TGF-b for different
periods of time, and analyzing the expression of CTGF
messenger RNA (mRNA) and protein by northern and west-
ern blots. As shown in Fig 1B, CTGF mRNA was potently
induced 2 h after TGF-b addition, and the levels remained
elevated until 24 h. In addition, plasminogen activator in-
hibitor (PAI)-1 mRNA were detected 2 h after TGF-b stim-
ulation, whereas biglycan mRNA were potently upregulated
after 24-h TGF-b treatment (Fig 1B). Western blot analyses
showed that CTGF protein appeared in the cell layer of
TGF-b-treated fibroblasts even after 2 h, whereas soluble
CTGF was detected in the conditioned media after 18 h of
treatment (Fig 1C). The levels of soluble CTGF were ele-
vated up to 48 h, indicating that the production of CTGF
protein is rapidly induced after TGF-b addition, but it accu-
mulates in the conditioned media relatively slowly.
TGF-b-induced expression of CTGF is mediated by
Smad3 In order to elucidate the role of Smad signal-
ing pathway in TGF-b-induced expression of endogenous
CTGF gene in human gingival fibroblasts, we utilized adeno-
viral gene delivery of Smad7 (RAdSmad7) and dominant-
negative Smad3 (RAdSmad3DN). Human gingival fibro-
blasts were infected with the corresponding recombinant
adenoviruses and with empty control virus RAdpCA3, treat-
ed with TGF-b for 24 h, after which the cells were harvested
and analyzed for the expression of CTGF by western blot
hybridization. TGF-b potently induced the accumulation of
CTGF in the cell layer of control virus RAdpCA3-infected
cells, as compared with untreated control (Fig 2A). Adeno-
viral overexpression of Smad7 potently (by 73%) inhibited
Figure1
Expression of connective tissue growth factor (CTGF) is induced
by transforming growth factor-b (TGF-b) in human gingival fibro-
blasts. (A) Human gingival fibroblasts (HGF1–3) established from three
different donors were serum starved for 18 h, and subsequently treated
with TGF-b1 (5 ng per mL) for 24 h, as indicated. The conditioned
media and cell layers were harvested and analyzed by western blotting
for the production of CTGF, tissue inhibitor of metalloproteinases
(TIMP)-1, and Cyr61 with specific antibodies. (B,C) HGF were serum
starved for 18 h, and subsequently treated with TGF-b1 (5 ng per mL)
for different periods of time, as indicated. The cell layers were har-
vested for RNA extraction and analyzed for the expression of CTGF,
plasminogen activator inhibitor (PAI)-1, biglycan, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) messenger RNA by northern
blotting (B). Conditioned media were collected and analyzed for the
production of soluble CTGF, and the cell layers were analyzed for the
production of CTGF by western blotting (C).
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the effect of TGF-b on CTGF production, indicating that
Smad signaling pathway is essential for TGF-b-induced
CTGF expression. In addition, expression of dominant-
negative Smad3 inhibited TGF-b-induced expression of
CTGF, indicating that Smad3 specifically mediates the
upregulatory effect of TGF-b on CTGF gene expression.
Similarly, basal and TGF-b-induced Cyr61 expression
was suppressed by adenoviral expression of Smad7 and
Smad3DN (Fig 2A).
To further study the role of Smad signaling in the induc-
tion of endogenous CTGF production by TGF-b in human
gingival fibroblasts, we utilized adenoviral gene delivery of
wild-type Smad2 and Smad3, and dominant-negative
Smad3, and analyzed CTGF expression by northern and
western blots. As expected, a 24-h TGF-b treatment of
empty control virus RAd66 infected cells resulted in potent
induction of the expression of CTGF mRNA and protein, as
compared with untreated cells (Fig 2B and C). Interestingly,
the TGF-b-induced expression of CTGF mRNA was clearly
(by 3-fold) enhanced by Smad3 overexpression, as com-
pared with RAd66-infected cells treated with TGF-b (Fig
2B), resulting in a marked increase in secretion of soluble
CTGF in the conditioned media of fibroblasts (Fig 2C). In
accordance with the above results, expression of dominant-
negative Smad3 potently inhibited the TGF-b-induced ex-
pression of CTGF mRNA by 85%, indicating that Smad3 is
essential for the induction of CTGF production by TGF-b
(Fig 2B and C). In contrast, overexpression of Smad2 had
no effect on the induction of CTGF expression by TGF-b
(Fig 2B and C). The production of TIMP-1 was not affected
by Smad2 or Smad3 overexpression in the absence or
presence of TGF-b (Fig 2C).
Consistent with our previous results (Leivonen et al,
2002), the expression of PAI-1 mRNA was potently upreg-
ulated upon TGF-b treatment of gingival fibroblasts, and
overexpression of Smad3 enhanced the TGF-b-induced
levels of PAI-1 mRNA by 5-fold (Fig 2B). In addition, over-
expression of dominant-negative Smad3 resulted in potent
inhibition of TGF-b-induced expression of PAI-1 by 50%,
indicating that it is mediated by Smad3.
Biglycan expression in human gingival fibroblasts is po-
tently induced by TGF-b (Ka¨ha¨ri et al, 1991), and recent
studies have identified biglycan as a Smad-responsive gene
in pancreatic cells (Chen et al, 2002; Ungefroren et al, 2003).
Therefore, we examined the role of Smad signaling in reg-
ulating biglycan gene expression in gingival fibroblasts.
TGF-b potently induced the expression of biglycan mRNA,
and the overexpression of Smad3 enhanced the effect of
TGF-b by 2-fold (Fig 2B). In addition, inhibition of the Smad
pathway by dominant-negative Smad3 suppressed the ex-
pression of biglycan mRNA by 75%. These results indicate
that biglycan is a Smad3-responsive gene in human gingival
fibroblasts.
ERK1/2 mediates TGF-b-induced expression of CTGF in
human gingival ﬁbroblasts TGF-b activates ERK1/2 and
p38 MAPK pathways in human gingival fibroblasts (Ravanti
et al, 1999). To examine the role of ERK1/2 and p38 MAPK
pathways in mediating the effect of TGF-b on CTGF gene
expression, we used PD98059 (30 mM), an inhibitor for
MEK1, the upstream activator of ERK1/2, and SB203580
(10 mM), a specific chemical inhibitor for p38 MAPK. Gin-
gival fibroblasts were serum-starved for 18 h, and subse-
quently treated with the corresponding MAPK inhibitors for
1 h prior to addition of TGF-b. TGF-b-induced CTGF mRNA
was detected 3 h after TGF-b treatment, and their levels
were further increased after 8 or 16 h of TGF-b treatment
(Fig 3A). Interestingly, PD98059 potently (by 80%) inhibited
the effect of TGF-b on CTGF mRNA abundance, whereas
SB203580 slightly (by 30%) inhibited the effect of TGF-b,
noted after 16 h incubation. These results indicate that
the ERK1/2 pathway mediates the effects of TGF-b on
Figure 2
Smad3 mediates transforming growth factor-b- (TGF-b-) induced
expression of connective tissue growth factor (CTGF) in human
gingival fibroblasts. (A) Human gingival fibroblasts were infected
with recombinant adenoviruses for dominant-negative Smad3 (RA-
dSmad3DN), and wild-type inhibitory Smad7 (RAdSmad7), and with
empty control virus RAdpCA3 at multiplicity of infection (MOI) 500. After
infection, the cells were incubated for 24 h, and treated with TGF-b1 (5
ng per mL) for 24 h, as indicated. The cell layers were harvested and
analyzed for the levels of CTGF and Cyr61 by western blotting using
corresponding antibodies. Equal loading was confirmed by probing the
same filter with specific antibody against b-actin. The levels of CTGF
and Cyr61 quantitated by densitometric scanning and normalized to
b-actin levels are shown below the blot relative to the levels in RA-
dpCA3-infected control cells (1.0). (B,C) Human gingival fibroblasts
were infected with recombinant adenoviruses for Smad2 and Smad3
(RAdSmad2 and RAdSmad3, respectively), and RAdSmad3DN, and
with control virus RAd66 at MOI 500, and treated with TGF-b1 (5 ng per
mL) for 24 h, as indicated. Total cellular RNA were analyzed for the
expression of CTGF, plasminogen activator inhibitor (PAI)-1, biglycan,
or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) messenger
RNA by northern blotting (B). Conditioned media were analyzed for the
levels of CTGF and tissue inhibitor of metalloproteinases (TIMP)-1, and
the cell layers for the expression of CTGF and Cyr61 with western
blotting (C).
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CTGF gene expression. In addition, PD98059 suppressed
the TGF-b-induced PAI-1 mRNA levels by 80%–90% (Fig
3A), indicating that in gingival fibroblasts ERK1/2 also me-
diates TGF-b-induced expression of PAI-1. In comparison,
PD98059 had no marked effect on the levels of biglycan
mRNA detected after 16-h TGF-b treatment (Fig 3A). In
contrast, SB203580 potently (by 90%) inhibited the effect of
TGF-b on biglycan gene expression, providing evidence
that the activity of p38 MAPK is essential for TGF-b-induced
biglycan expression (Fig 3A). This is in accordance with
recent observations showing that MKK6/p38 pathway is
needed for induction of biglycan gene expression by TGF-b
(Ungefroren et al, 2003).
To further elucidate the role of ERK1/2 and p38 MAPK in
TGF-b-induced expression of CTGF, we treated gingival
fibroblasts with the corresponding MAPK inhibitors and
TGF-b for 24 h, and analyzed the conditioned medium and
cell layers for the production of CTGF by western blotting. In
accordance with the above observations, a 24-h TGF-b
treatment of cells potently induced the production of CTGF
protein both into the cell layer and conditioned media
(Fig 3B). Consistent with the results shown in Fig 3A, inhi-
bition of MEK1 activity by PD98059 totally abrogated TGF-
b-induced CTGF accumulation in the cell layer and secre-
tion into conditioned media (Fig 3B). In contrast, SB203580
slightly reduced the TGF-b-induced accumulation of CTGF
to the cell layer, but this had no marked effect on the pro-
duction of soluble CTGF (Fig 3B). These results indicate that
ERK1/2 signaling pathway is essential for the TGF-b-
induced expression of CTGF in human gingival fibroblasts.
In comparison, neither PD98059 nor SB203580 had any
marked effect on Cyr61 or TIMP-1 production (Fig 3B).
Co-expression of Smad3 with constitutively active
MEK1 results in induction of CTGF production in the
absence of TGF-b stimulation Smad signaling is also reg-
ulated through crosstalk with other signaling cascades, e.g.,
MAPK pathways p38, ERK1/2 and JNK, and Cam kinase II
(Brown et al, 1999; Wicks et al, 2000; Blanchette et al, 2001;
Watanabe et al, 2001; Leivonen et al, 2002). Furthermore,
ERK1/2 has been shown to activate Smad2 or Smad3 by
phosphorylation (Funaba et al, 2002; Hayashida et al, 2003).
As TGF-b treatment of gingival fibroblasts leads to rapid
phosphorylation of ERK1/2 (Ravanti et al, 1999), and the
above results show the involvement of Smad3 and ERK1/2
in TGF-b-induced CTGF expression, we examined the pos-
sible crosstalk between Smad3 and ERK1/2 signaling path-
ways in regulating the CTGF gene expression in human
gingival fibroblasts. We utilized adenovirus RAdMEK1CA for
delivery of constitutively active MEK1, the upstream acti-
vator or ERK1/2, and adenovirus for constitutively very
active MKK3b (RAdMKK3bE), the upstream activator of
p38a, together with Smad3 adenovirus. Gingival fibroblasts
were infected with the corresponding adenoviruses, incu-
bated for 24 h, and the conditioned media and cell layers
were harvested for western analysis. In order to confirm that
ERK1/2 and p38 MAPK were activated by adenovirally ex-
pressed MEK1CA and MKK3bE, respectively, we first analy-
zed the levels of activated ERK1/2 and p38 in infected
fibroblasts by western blot. As shown in Fig 4A, infection of
cells with adenoviruses for constitutively active MKK3b and
MEK1 resulted in potent activation of p38 and ERK1/2
MAPK, respectively. Furthermore, overexpression of Smad3
had no effect on the phosphorylation of p38 or ERK1/2.
Phosphorylation of Smad3 in its C-terminal SSXS-motif
could not be detected in these samples (data not shown).
Next, we analyzed the production of CTGF in the same
cells by western blotting. In the absence of TGF-b, activa-
tion of ERK1/2 by MEK1CA and simultaneous co-expression
of Smad3 resulted in significant induction of CTGF accu-
mulation into the cell layer and secretion into the condi-
tioned media of infected gingival fibroblasts (Fig 4A). On the
contrary, activation of endogenous p38a by constitutively
active MKK3bE and simultaneous co-expression of Smad3
or MEK1CA had no effect on the accumulation of CTGF in
the cell layer or on the conditioned media of infected gin-
gival fibroblasts (Fig 4A and B). Interestingly, activation of
ERK1/2 and simultaneous overexpression of Smad3 also
resulted in upregulation of Cyr61 production in the cell layer
or infected cells (Fig 4A). Activation of ERK1/2 by MEK1CA
slightly augmented pro-matrix metalloproteinase (MMP)-1
production, and co-expression of Smad3 further induced
pro-MMP-1 protein production (Fig 4B). In addition, activa-
tion of p38 together with activated ERK1/2 resulted in
potent induction of pro-MMP-1 protein levels (Fig 4B).
Activation of ERK1/2 by constitutively active MEK1 also
enhanced the production of TIMP-1 in the conditioned me-
dia of the same cells (Fig 4B).
Discussion
CTGF is a pleiotropic growth factor, the expression of which
is rapidly induced by TGF-b in fibroblastic cells. It belongs
to the CCN family of growth factors, the other members
including Cyr61-, Nov-, and Wnt-induced secreted pro-
teins-1, -2, and -3 (WISP-1, -2, and -3). CCN members ex-
Figure 3
Transforming growth factor-b- (TGF-b-) induced expression of
connective tissue growth factor (CTGF) in human gingival fibro-
blasts is mediated by extracellular signal-regulated kinase (ERK)1/
2. (A) Human gingival fibroblasts were serum starved for 18 h, and
treated for 1 h with PD98059 (30 mM), or SB203580 (10 mM), specific
chemical inhibitors for mitogen-activated protein kinase/ERK kinase
(MEK)1 or p38, respectively. Subsequently, TGF-b1 (5 ng per mL) was
added, and the cultures were incubated for 3, 8, or 16 h, as indicated.
Total cellular RNA were harvested and analyzed for the levels of CTGF,
plasminogen activator inhibitor (PAI)-1, biglycan, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) messenger RNA by northern
blot hybridizations. (B) Human gingival fibroblasts were treated with
PD98059 or SB203580, and TGF-b1, as in (A) and incubated for 24 h.
The conditioned media were analyzed for the levels of CTGF and tissue
inhibitor of metalloproteinases (TIMP)-1, and the cell layers for the ex-
pression of CTGF and Cyr61 with western blotting.
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hibit a wide range of functions that regulate biological proc-
esses such as cell adhesion, angiogenesis, and tissue fi-
brosis. CTGF is a potent enhancer of fibroblast proliferation,
chemotaxis, and extracellular matrix (ECM) deposition, and
it is thought to mediate some of the fibrogenic effects of
TGF-b (Frazier et al, 1996).
In this study, we have elucidated in detail the cellular
signaling pathways involved in regulating the TGF-b-in-
duced expression of CTGF in human gingival fibroblasts.
Major cell signaling pathways activated by TGF-b include
MAPK pathways ERK1/2, JNK, and p38, and the Smad
pathway. The Smad pathway is activated when TGF-b type I
receptor kinase ALK5 phosphorylates SSXS motif in the C-
terminus of receptor-regulated Smad2 and Smad3. TGF-b
is a potent stimulator of the production of many ECM com-
ponents, and Smads are involved in mediating the effects of
TGF-b on the expression of e.g., collagenase-3 (MMP-13),
biglycan, aggrecan, PAI-1, type I collagen, and type VII
collagen (Dennler et al, 1998; Watanabe et al, 2001; Leiv-
onen et al, 2002; Ungefroren et al, 2003). Although the role
of different cellular signaling pathways in regulating the ac-
tivity of CTGF promoter has been widely studied (Groten-
dorst et al, 1996; Holmes et al, 2001; Chen et al, 2002;
Leask et al, 2003), there are only a few reports studying the
regulation of endogenous CTGF gene expression. There-
fore, we used our recently constructed recombinant Smad
adenoviruses (Leivonen et al, 2002) in dissecting the role of
Smad signaling pathway in regulating the endogenous
CTGF gene expression in human gingival fibroblasts. The
results of this study show that Smad3, but not Smad2, me-
diates the effect of TGF-b on the production of endogenous
CTGF. Adenoviral overexpression of Smad3 resulted in a
significant enhancement in TGF-b-induced levels of CTGF
mRNA and resulted in a potent increase in the secretion of
soluble CTGF. In addition, Smad7 and dominant-negative
Smad3 potently inhibited the effect of TGF-b on CTGF pro-
duction. These results are in accordance with a previous
report, where Smad3 and Smad4 mediated the activation of
CTGF promoter by TGF-b in the human lung and skin fib-
roblasts (Holmes et al, 2001). Interestingly, our results also
demonstrate that the basal and TGF-b-induced expression
of Cyr61 is Smad-dependent. Inhibition of Smad signaling
by adenovirally delivered dominant-negative Smad3 and
inhibitory Smad7 potently suppressed Cyr61 production in
the cell layer of infected fibroblasts. It seems that the reg-
ulation of CCN family members CTGF and Cyr61 differs
from the regulation of the third member of the family, Nov,
as TGF-b downregulates the expression of Nov in a Smad-
independent manner (Lafont et al, 2002).
In gingival fibroblasts, TGF-b stimulation leads to acti-
vation of ERK1/2 and p38 MAPK pathways (Ravanti et al,
1999). Therefore, we elucidated the role of these signaling
cascades in mediating the effects of TGF-b on CTGF gene
expression. MEK1/2 inhibitor PD98059 abrogated the ef-
fects of TGF-b on the induction of CTGF gene expression,
whereas p38 inhibitor SB203580 had no marked effect on
the production and release of CTGF by fibroblasts. This is in
accordance with recent results showing that ERK1/2 is in-
volved in the activation of CTGF promoter by TGF-b in skin
fibroblasts (Leask et al, 2003). In addition, our results pro-
vide evidence for the importance of crosstalk between
ERK1/2 and Smad3 signaling in CTGF regulation, as
co-expression of Smad3 with constitutively active MEK1
resulted in potent induction of CTGF production without
exogenous TGF-b stimulation. There is recent evidence
that kinases of MAPK pathways are capable of activat-
ing Smad signaling. For example, activated ERK1/2 can
phosphorylate Smad2 in its linker region and N-terminal
domain, but not in the usual C-terminal SSXS motif, which
is phosphorylated by ALK5 (Funaba et al, 2002). Further-
more, MEK1/2/ERK1/2 inhibitors PD98059 and UO126
decrease the total serine phosphorylation of Smad2/3, but
not phosphorylation of the C-terminal SSXS motif, sug-
gesting that ERK1/2 is capable of phosphorylating Smad
in a region other than the C-terminus (Hayashida et al,
2003). In our study, phosphorylated Smad3 could not be
detected in the cell lysates where Smad3 was co-ex-
pressed with constitutively active MEK1, as the phospho-
Figure 4
Expression of Smad3 and activation
of extracellular signal-regulated kinase
(ERK)1/2 results in induction of con-
nective tissue growth factor (CTGF)
gene expression in the absence of
transforming growth factor-b (TGF-b)
stimulation. (A, B) Human gingival fibro-
blasts were infected with recombinant
adenoviruses for constitutively active mi-
togen-activated protein kinase/ERK kin-
ase (MEK)1 (RAdMEK1CA), constitutively
active MKK3b (RAdMKK3bE), Smad3
(RAdSmad3) and control virus RAd66, as
indicated at multiplicity of infection 500.
After 24 h incubation, the cell layers were
analyzed for the levels of CTGF and Cyr61,
and for the levels of activated p38 MAPK
(p-p38) and ERK1/2 (p-ERK1/2) and total
p38 and ERK1/2 with specific antibodies
(A). Conditioned media were harvested
and analyzed for the production of CTGF,
pro-matrix metalloproteinase-1, and tissue
inhibitor of metalloproteinases (TIMP-1) (B).
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specific antibody used here detects only Smad3 phos-
phorylated in its C-terminus (Piek et al, 1999; Dooley et al,
2001). It is therefore possible that ERK1/2 also induces ac-
tivation of Smad3 in our model. This could explain why
Cyr61 is upregulated when Smad3 is co-expressed with
activated ERK1/2. Inhibition of ERK1/2 pathway by
PD98059 had no effect on TGF-b-induced Cyr61 expres-
sion, suggesting that ERK1/2 is not alone involved in the
regulation of Cyr61. On the contrary, our results demon-
strated that Smad3 mediated the expression of Cyr61. To-
gether, these results suggest that activation of Smad3 by
ERK1/2 is sufficient to induce Cyr61 expression in the ab-
sence of TGF-b under the conditions where Smad3 is co-
expressed with MEK1-activated ERK1/2.
Although CTGF is a secreted soluble protein, it also as-
sociates with the ECM (Steffen et al, 1998). In this study,
secretion of soluble CTGF in the conditioned media of TGF-
b-stimulated gingival fibroblasts was markedly increased
when Smad3 was overexpressed. In addition, co-expres-
sion of Smad3 with constitutively active MEK1 resulted in
potent secretion of soluble CTGF by these cells. Interest-
ingly, the expression of MMP-1 was also potently upregu-
lated, when Smad3 was co-expressed with constitutively
active MEK1, i.e., the secretion of CTGF in the conditioned
media correlated with the production of MMP-1. MMPs are
a large family of zinc-dependent endopeptidases collec-
tively capable of degrading essentially all components of
the ECM. Moreover, MMPs can cleave molecules other than
ECM components, such as interleukin-1b and Fas-ligand
(Ito et al, 1996; Mitsiades et al, 2001). There is also recent
evidence that certain MMPs can cleave CTGF (Hashimoto
et al, 2002). It is therefore possible, that MMPs are involved
in the release of CTGF from the ECM into the conditioned
media of fibroblasts.
In conclusion, the results of this study demonstrate that
activation of Smad3 and ERK1/2 signaling cooperatively
mediates the stimulatory effect of TGF-b on CTGF produc-
tion in human fibroblasts (Fig 5). It is likely, that TGF-b elic-
ited induction of CTGF expression by an interplay between
Smad3 and ERK1/2 plays a role in situations in which CTGF
mediate the effects of TGF-b, such as tissue repair and
fibrosis. It is conceivable that this interplay can be exploited
in therapeutic targeting of CTGF expression, e.g., in fibrotic
conditions.
Materials and Methods
Cell cultures and reagents Human gingival fibroblasts were es-
tablished from three healthy donors (Ravanti et al, 1999; Leivonen
et al, 2002). All studies were approved by the ethical committee of
the University of Turku. Participants gave their written informed
consent, and the study was conducted according to the declara-
tion of Helsinki. The cells were grown in Dulbecco’s Modified Ea-
gle’s Medium (DMEM; Sigma, St Louis, Missouri) supplemented
with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU per mL
penicillin-G, and 100 mg per mL streptomycin. Human recombinant
TGF-b1 was obtained from Sigma, and p38 MAPK inhibitor
SB203580 and MEK1/2 inhibitor PD98059 were from Calbiochem
(San Diego, California).
Transduction of human gingival ﬁbroblasts with recombinant
adenoviruses The construction of empty control virus RAdpCA3
and recombinant adenoviruses RAdSmad2, RAdSmad3, RAdS-
mad4 for HA-tagged Smad2, Smad3, and Smad4, respectively,
has been described previously (Leivonen et al, 2002). Recombinant
adenoviruses for Smad7 (RadSmad7) (Fujii et al, 1999) and dom-
inant-negative Smad3 (RAdSmad3DN) (Pardali et al, 2000) were
kindly provided by Dr Aristidis Moustakas (Ludwig Institute for
Cancer Research, Uppsala, Sweden). Adenovirus for constitutively
active MEK1 (RAdMEK1CA) (Foschi et al, 1997) was kindly provided
by Dr Marco Foschi (University of Florence, Italy), and adenovirus
for constitutively active MKK3b (RAdMKK3bE) (Wang et al, 1998)
by Dr Jiahuai Han (Scripps Research Institute, La Jolla, California).
Control adenovirus RAd66 (Wilkinson and Akrigg, 1992) was kindly
provided by Dr Gavin W.G. Wilkinson (University of Cardiff, Cardiff,
UK).
Adenoviral infections of human gingival fibroblasts were per-
formed as previously (Leivonen et al, 2002). Briefly, cells were in-
fected in suspension with a multiplicity of infection 500, plated, and
incubated for 18 h in DMEM with 1% FCS. Thereafter, the medium
was replaced with DMEM without FCS, and the incubations were
continued for 24 h. The cultures were treated with TGF-b1 (5 ng per
mL) for 24 h, as indicated. Thereafter, the conditioned media were
harvested, and analyzed for the production of CTGF, pro-MMP-1,
or TIMP-1 by western blotting. The cell layers were harvested
either for RNA extraction to detect CTGF, PAI-1, biglycan, or MMP-
1 mRNA, or for the determination of CTGF or Cyr61 proteins and
activated p38 and ERK1/2 from the cell lysates by western blotting.
Immunoblotting and antibodies Western blottings were per-
formed as described previously (Leivonen et al, 2002). Polyclonal
rabbit anti-CTGF antibody pAb2 was obtained from Fibrogen
(South San Francisco, California). Polyclonal antibody against
Cyr61 was from Santa Cruz Biotechnology (Santa Cruz, California),
and polyclonal anti-TIMP-1 from Chemicon International (Teme-
cula, California). Polyclonal rabbit antiserum raised against human
MMP-1 was a kind gift from Dr Henning Birkedal-Hansen (NIDCR,
National Institutes of Health, Bethesda, Maryland). Polyclonal an-
tibodies for phospho-p38, p38, phospho-ERK1/2, and ERK1/2
were from Cell Signaling Technology (Beverly, Massachussetts),
and monoclonal antibody for b-actin was from Sigma. Antiserum
for phospho-Smad1, which shows cross-reactivity with phos-
phorylated Smad3, was a kind gift from Dr Aristidis Moustakas
(Ludwig Institute for Cancer Research) (Piek et al, 1999; Dooley
et al, 2001). The blots were visualized by the enhanced chemilumi-
Figure5
A schematic representation of the transforming growth factor-b
(TGF-b) signaling pathways regulating connective tissue growth
factor (CTGF) gene expression in human gingival fibroblasts. Stim-
ulation of human gingival fibroblasts with TGF-b results in activation of
Smad3 and extracellular signal-regulated kinase (ERK)1/2 mitogen-ac-
tivated protein kinase (MAPK). Smad3 associates with Smad4, and
mediates induction of CTGF expression by TGF-b. Smad7 and dom-
inant-negative Smad3 (Smad3DN) inhibit phosphorylation of Smad3 by
TGF-b receptor complex. Activated ERK1/2 and Smad3 cooperate in
regulating the expression of CTGF. MAPK/ERK kinase (MEK)1/2 activity
is inhibited by specific chemical inhibitor, PD98059.
SMAD3 AND ERK1/2 REGULATE CTGF EXPRESSION 1167124 : 6 JUNE 2005
nescence detection system (Amersham Pharmacia Biotech, Buck-
inghamshire, UK), and quantitated by densitometric scanning.
Northern blot hybridizations Total cellular RNA was extracted
with Qiagen’s Rapid RNA Purification Kit (Qiagen, Chatsworth,
California), and northern blot hybridizations were performed as
described previously (Leivonen et al, 2002). For hybridizations, a
1.2-kb human CTGF complementary DNA (cDNA), a 2.0-kb human
MMP-1 cDNA (Goldberg et al, 1986), human PAI-1 cDNA (Keski-
Oja et al, 1988), a 1.7-kb human biglycan cDNA (Fisher et al, 1989),
and a 1.3-kb rat glyceraldehyde-3-phosphate dehydrogenase
cDNA (Fort et al, 1985) were used. The 1.2 kb cDNA for the cod-
ing region of human CTGF (Bradham et al, 1991) was obtained by
RT-PCR of TGF-b-treated gingival fibroblast RNA samples using
specific primers (sense 50-ATC GAT ATC CGC AGT GCC AAC CAT
GAC-30, and antisense 30-GTA CCG TAC TTC GGT CTC TCC TAG
GAC A-50).
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